Skip to main content
Top
Published in: BMC Nephrology 1/2018

Open Access 01-12-2018 | Case report

Myocardial remodeling after kidney transplantation: a case report

Authors: Marceli Lukaszewski, Kinga Kosiorowska, Dorota Kaminska, Marta Obremska, Oktawia Mazanowska, Magdalena Krajewska

Published in: BMC Nephrology | Issue 1/2018

Login to get access

Abstract

Background

Lupus nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE) and is often the most serious organ complication and the cause of premature death of such a patient. Most of other organs and systems can be also affected. A typical complication is a cardiovascular involvement leading to the development of heart failure. According to current therapeutic standards, kidney transplantation is the treatment of choice in patients with renal failure in course of LN. On the contrary, a kidney transplantation in a patient with an additional heart disease poses a serious clinical challenge.

Case presentation

We present a case of a 49-year-old woman with renal and heart failure following a long-term SLE prepared for kidney transplantation. During the SLE course, the function of the heart and kidneys gradually deteriorated. The patient required the initiation of renal replacement therapy and was dialyzed until a kidney transplantation for 4 years. In the preparation of the patient for the surgical procedure, due to the extremely low ejection fraction, it was decided to include cardioprotective treatment with Levosimendan. The postoperative period was not straightforward but successful. In the monthly and five-month follow-up, a continuous improvement of heart function with normal renal function was noted.

Conclusions

Kidney transplantation in patients with lupus suffering from heart failure requires the involvement of a team of specialists. Patients with extremely low ejection fraction in the perioperative period should undergo careful hemodynamic supervision in the intensive care unit. Cardioprotective and thus nephroprotective Levosimendan therapy together with optimal fluid and hemodynamic therapy in the peri-transplant period may be a bridge for heart remodeling after kidney transplantation.
Literature
1.
go back to reference Yilmaz MB, et al. Renal Effects of Levosimendan: A Consensus Report. Cardiovasc Drugs Ther. 2013;27(6):581–90. Yilmaz MB, et al. Renal Effects of Levosimendan: A Consensus Report. Cardiovasc Drugs Ther. 2013;27(6):581–90.
2.
go back to reference Foderaro AE, et al. Echocardiographic pulmonary hypertension predicts post-transplantation renal allograft failure. Transplant Proc. 2017;49(6):1256–61.CrossRef Foderaro AE, et al. Echocardiographic pulmonary hypertension predicts post-transplantation renal allograft failure. Transplant Proc. 2017;49(6):1256–61.CrossRef
3.
go back to reference Tarner IH, Lange U, Madlener K, Classen K, Kandolf R, Sperzel J. Der Wolf im Schafspelz: atypischer systemischer Lupus erythematodes (SLE) mit führender kardiovaskulärer Symptomatik. Med Klin. 2010;4(4):300–4. Tarner IH, Lange U, Madlener K, Classen K, Kandolf R, Sperzel J. Der Wolf im Schafspelz: atypischer systemischer Lupus erythematodes (SLE) mit führender kardiovaskulärer Symptomatik. Med Klin. 2010;4(4):300–4.
4.
go back to reference Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26(5):502–9.CrossRef Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26(5):502–9.CrossRef
5.
go back to reference Tsai H, et al. Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study. Transpl Int. 2017;30(11):1161–71.CrossRef Tsai H, et al. Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study. Transpl Int. 2017;30(11):1161–71.CrossRef
6.
go back to reference Jeloka TK, et al. Renal transplant outcome in high-cardiovascular risk recipients. Clin Transpl. 2007;21(5):609–14.CrossRef Jeloka TK, et al. Renal transplant outcome in high-cardiovascular risk recipients. Clin Transpl. 2007;21(5):609–14.CrossRef
7.
go back to reference Mimura I, Kawarazaki H, Momose T, Shibagaki Y, Fujita T. Improvement of cardiac function after kidney transplantation with dilated cardiomyopathy and long dialysis vintage. Clin Kidney J. 2009;2(6):479–81.CrossRef Mimura I, Kawarazaki H, Momose T, Shibagaki Y, Fujita T. Improvement of cardiac function after kidney transplantation with dilated cardiomyopathy and long dialysis vintage. Clin Kidney J. 2009;2(6):479–81.CrossRef
8.
go back to reference Kute VB, et al. Significant benefits after renal transplantation in patients with chronic heart failure and chronic kidney disease heart failure and chronic kidney disease. Ren Fail. 2014;36(6):854–8. Kute VB, et al. Significant benefits after renal transplantation in patients with chronic heart failure and chronic kidney disease heart failure and chronic kidney disease. Ren Fail. 2014;36(6):854–8.
9.
go back to reference Garcia-Covarrubias L, et al. Cardiac remodeling in structure and function six months after kidney transplantation. Transplant Proc. 2018;50(2):454–7.CrossRef Garcia-Covarrubias L, et al. Cardiac remodeling in structure and function six months after kidney transplantation. Transplant Proc. 2018;50(2):454–7.CrossRef
10.
go back to reference Wali RK, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. 2005;45(7):1051–60.CrossRef Wali RK, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. 2005;45(7):1051–60.CrossRef
11.
go back to reference Melchor JL, Espinoza R, Gracida C. Kidney transplantation in patients with ventricular ejection fraction less than 50 percent: features and posttransplant outcome. Transplant Proc. 2002;34(7):2539–40.CrossRef Melchor JL, Espinoza R, Gracida C. Kidney transplantation in patients with ventricular ejection fraction less than 50 percent: features and posttransplant outcome. Transplant Proc. 2002;34(7):2539–40.CrossRef
12.
go back to reference Baysal A, Yanartas M, Dogukan M, Gundogus N, Kocak T, Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28(3):586–94.CrossRef Baysal A, Yanartas M, Dogukan M, Gundogus N, Kocak T, Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28(3):586–94.CrossRef
13.
go back to reference Knezevic I, et al. The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial. Clin Transpl. 2014;28(10):1105–11.CrossRef Knezevic I, et al. The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial. Clin Transpl. 2014;28(10):1105–11.CrossRef
14.
go back to reference Schmid S, Jungwirth B. Anaesthesia for renal transplant surgery: an update. Eur J Anaesthesiol. 2012;29(12):552–8.CrossRef Schmid S, Jungwirth B. Anaesthesia for renal transplant surgery: an update. Eur J Anaesthesiol. 2012;29(12):552–8.CrossRef
15.
go back to reference Mittel AM, Wagener G. Anesthesia for Kidney and Pancreas Transplantation. Anesthesiol Clin. 2017;35(3. Elsevier Inc):439–52.CrossRef Mittel AM, Wagener G. Anesthesia for Kidney and Pancreas Transplantation. Anesthesiol Clin. 2017;35(3. Elsevier Inc):439–52.CrossRef
16.
go back to reference Lionaki S. Kidney transplantation in patients with systemic lupus erythematosus. World J Transplant. 2014;4(3):176.CrossRef Lionaki S. Kidney transplantation in patients with systemic lupus erythematosus. World J Transplant. 2014;4(3):176.CrossRef
17.
go back to reference Tweezer-Zaks N, Zandman-Goddard G. A Long-Term Follow-up after Cardiac Transplantation in a Lupus Patient Case Report and Review of the Literature. Ann N Y Acad Sci. 2007;543:539–43. Tweezer-Zaks N, Zandman-Goddard G. A Long-Term Follow-up after Cardiac Transplantation in a Lupus Patient Case Report and Review of the Literature. Ann N Y Acad Sci. 2007;543:539–43.
18.
go back to reference Hernández K, et al. Cardiac remodeling in structure and function six months after kidney transplantation. Transplant Proc. 2018;50(2):454–7.CrossRef Hernández K, et al. Cardiac remodeling in structure and function six months after kidney transplantation. Transplant Proc. 2018;50(2):454–7.CrossRef
19.
go back to reference Karthikeyan V, et al. Impact of pre-existing left ventricular dysfunction on kidney transplantation outcomes: implications for patient selection. Transplant Proc. 2011;43(10):3652–6. Karthikeyan V, et al. Impact of pre-existing left ventricular dysfunction on kidney transplantation outcomes: implications for patient selection. Transplant Proc. 2011;43(10):3652–6.
20.
go back to reference Hawwa N, Shrestha K, Hammadah M, Yeo PSD, Fatica R, Tang WHW. Reverse remodeling and prognosis following kidney transplantation in contemporary patients with cardiac dysfunction. J Am Coll Cardiol. 2015;66(16):1779–87.CrossRef Hawwa N, Shrestha K, Hammadah M, Yeo PSD, Fatica R, Tang WHW. Reverse remodeling and prognosis following kidney transplantation in contemporary patients with cardiac dysfunction. J Am Coll Cardiol. 2015;66(16):1779–87.CrossRef
21.
go back to reference Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013;38(5):341–9.CrossRef Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013;38(5):341–9.CrossRef
22.
go back to reference Papp Z, et al. Levosimendan: molecular mechanisms and clinical implications. Int J Cardiol. 2012;159(2):82–7.CrossRef Papp Z, et al. Levosimendan: molecular mechanisms and clinical implications. Int J Cardiol. 2012;159(2):82–7.CrossRef
23.
go back to reference Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan Improves Renal Function in Patients With Advanced Chronic Heart Failure Awaiting Cardiac Transplantation. J Card Fail. 2007;13(6):417–21. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan Improves Renal Function in Patients With Advanced Chronic Heart Failure Awaiting Cardiac Transplantation. J Card Fail. 2007;13(6):417–21.
24.
go back to reference Fedele F, Karason K, Matskeplishvili S. Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. Eur Heart J Suppl. 2017;19:22–8. Fedele F, Karason K, Matskeplishvili S. Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. Eur Heart J Suppl. 2017;19:22–8.
25.
go back to reference Grossini E, et al. Protective effects elicited by Levosimendan against liver ischemia / reperfusion injury in anesthetized rats. Liver Transpl. 2014;20(3):361–75. Grossini E, et al. Protective effects elicited by Levosimendan against liver ischemia / reperfusion injury in anesthetized rats. Liver Transpl. 2014;20(3):361–75.
26.
go back to reference Guarracino F, Heringlake M, Cholley B, Bettex D, Bouchez S, Lomivorotov VV. The use of Levosimendan in cardiac surgery: an update after the LEVO-CTS, CHEETAH, and LICORN trials in the light of clinical practice. J Cardiovasc Pharmacol. 2018;71(1):1-9. Guarracino F, Heringlake M, Cholley B, Bettex D, Bouchez S, Lomivorotov VV. The use of Levosimendan in cardiac surgery: an update after the LEVO-CTS, CHEETAH, and LICORN trials in the light of clinical practice. J Cardiovasc Pharmacol. 2018;71(1):1-9.
Metadata
Title
Myocardial remodeling after kidney transplantation: a case report
Authors
Marceli Lukaszewski
Kinga Kosiorowska
Dorota Kaminska
Marta Obremska
Oktawia Mazanowska
Magdalena Krajewska
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2018
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-018-1185-x

Other articles of this Issue 1/2018

BMC Nephrology 1/2018 Go to the issue